Stabilized 29-amino acid GHRH analogue without the DAC modification of CJC-1295. Shorter acting than CJC-1295-DAC — produces physiological-style GH pulses. Often combined with GHRP-2 or ipamorelin for synergistic GH release.
15–30 minutes; short enough for pulsatile physiological GH mimicry
SKUs
1
Evidence
Moderate Evidence
Mod GRF 1-29 is another name for CJC-1295 without DAC — a modified GHRH analog designed to have a longer half-life than natural GHRH while still producing a pulse-like pattern of GH stimulation rather than a continuous flat elevation. The 1-29 refers to the first 29 amino acids of GHRH, which is the shortest active fragment of the hormone.
Growth Hormone Pulse Research
Mod GRF 1-29 is designed to amplify natural GH pulses by extending the GHRH signal from minutes to about 30 minutes to 2 hours. Administered around the time of natural GH pulse events, it produces a larger pulse that more closely resembles natural GH secretion patterns than continuous stimulation.
Combined Secretagogue Research
Like CJC-1295 without DAC, Mod GRF 1-29 is commonly combined with ipamorelin or other GHRPs in research protocols. The combination activates both GHRH and ghrelin receptor pathways simultaneously.
Produces GH pulse amplification when administered near natural pulse times.
Half-life significantly longer than natural GHRH (minutes extended to 30 minutes to 2 hours).
Often studied in combination with ipamorelin for additive GH stimulation.
No large independent randomized controlled trial data specific to this compound.
Mod GRF 1-29 and CJC-1295 without DAC are the same compound under different names, and all limitations of that compound apply here. Not FDA-approved, no large human trial data, and the long-term effects of repeated GH stimulation are not established. Authenticity and purity of research-grade material are important practical considerations.
Natural GHRH is released from the hypothalamus in brief bursts lasting only a few minutes before being broken down by enzymes in the bloodstream. Mod GRF 1-29 is the first 29 amino acids of GHRH with four amino acid substitutions that protect the peptide from those degrading enzymes. The result is a compound that still activates the GHRH receptor but lasts long enough in circulation to produce a meaningful GH response before being cleared. Because it is still cleared within hours (rather than days like the DAC version), the effect is more like amplifying a natural pulse than creating a continuous drip of GHRH stimulation.
Not FDA-approved. The same safety considerations as CJC-1295 without DAC apply. Extended GH and IGF-1 elevation from frequent repeated use carries the standard considerations around insulin resistance, fluid retention, and long-term growth-related effects. Research-grade purity is an important practical concern.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
100mcg per injection, 2–3 injections daily in combination protocols
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
GHRH(1-29)NH2 Analogues: Short-Acting GH Secretagogues for Pulsatile Release
Evidence on physical activity and osteoporosis prevention for people aged 65+ years: a systematic review to inform the WHO guidelines on physical activity and sedentary behaviour
Multi-Component Herbal Products in the Prevention and Treatment of Chemotherapy-Associated Toxicity and Side Effects: A Review on Experimental and Clinical Evidences
An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease
Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation
Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.